Annika Spottke
Overview
Explore the profile of Annika Spottke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
3036
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Menze I, Bernal J, Kaya P, Aki C, Pfister M, Geisendorfer J, et al.
Alzheimers Res Ther
. 2024 Nov;
16(1):242.
PMID: 39482759
Background: Perivascular space (PVS) enlargement in ageing and Alzheimer's disease (AD) and the drivers of such a structural change in humans require longitudinal investigation. Elucidating the effects of demographic factors,...
12.
Bernal J, Menze I, Yakupov R, Peters O, Hellmann-Regen J, Freiesleben S, et al.
Alzheimers Res Ther
. 2024 Oct;
16(1):240.
PMID: 39465440
Background: For over three decades, the concomitance of cortical neurodegeneration and white matter hyperintensities (WMH) has sparked discussions about their coupled temporal dynamics. Longitudinal studies supporting this hypothesis nonetheless remain...
13.
Fang R, Duering M, Bode F, Stosser S, Meissner J, Hermann P, et al.
Alzheimers Dement
. 2024 Oct;
20(12):8412-8428.
PMID: 39417418
Introduction: While incident ischemic lesions (IILs) are not unusual on follow-up magnetic resonance imaging (MRI) following stroke, their risk factors and prognostic significance remain unknown. Methods: In a prospective multicenter...
14.
Konig A, Kohler S, Troger J, Duzel E, Glanz W, Butryn M, et al.
Alzheimers Dement (Amst)
. 2024 Oct;
16(4):e70011.
PMID: 39376498
Introduction: We investigated the agreement between automated and gold-standard manual transcriptions of telephone chatbot-based semantic verbal fluency testing. Methods: We examined 78 cases from the Screening over Speech in Unselected...
15.
Wang X, Freiesleben S, Schneider L, Preis L, Priller J, Spruth E, et al.
Neurology
. 2024 Sep;
103(8):e209806.
PMID: 39303184
Background And Objectives: CSF biomarkers have immense diagnostic and prognostic potential for Alzheimer disease (AD). However, AD is still diagnosed relatively late in the disease process, sometimes even years after...
16.
Katzdobler S, Nubling G, Klietz M, Fietzek U, Palleis C, Bernhardt A, et al.
J Neurol
. 2024 Sep;
271(10):6991-6999.
PMID: 39254698
Background: Multiple system atrophy (MSA), an atypical parkinsonian syndrome, is a rapidly progressive neurodegenerative disease with currently no established fluid biomarkers available. MSA is characterized by an oligodendroglial α-synucleinopathy, progressive...
17.
Dunnwald M, Krohn F, Sciarra A, Sarkar M, Schneider A, Fliessbach K, et al.
bioRxiv
. 2024 Aug;
PMID: 39091766
Introduction: The Locus Coeruleus (LC) is linked to the development and pathophysiology of neurodegenerative diseases such as Alzheimer's Disease (AD). Magnetic Resonance Imaging based LC features have shown potential to...
18.
Preis L, Villringer K, Brosseron F, Duzel E, Jessen F, Petzold G, et al.
Alzheimers Res Ther
. 2024 Jul;
16(1):172.
PMID: 39085945
Background: Blood-brain barrier (BBB) alterations may contribute to AD pathology through various mechanisms, including impaired amyloid-β (Aβ) clearance and neuroinflammation. Soluble platelet-derived growth factor receptor beta (sPDGFRβ) has emerged as...
19.
Shao K, Hu X, Kleineidam L, Stark M, Altenstein S, Amthauer H, et al.
Alzheimers Dement
. 2024 Jul;
20(9):5926-5939.
PMID: 39072956
Introduction: Subjective cognitive decline (SCD) in amyloid-positive (Aβ+) individuals was proposed as a clinical indicator of Stage 2 in the Alzheimer's disease (AD) continuum, but this requires further validation across...
20.
Vogelgsang J, Hansen N, Stark M, Wagner M, Klafki H, Morgado B, et al.
Alzheimers Dement
. 2024 Jun;
20(8):5132-5142.
PMID: 38940303
Introduction: Blood-based biomarkers are a cost-effective and minimally invasive method for diagnosing the early and preclinical stages of amyloid positivity (AP). Our study aims to investigate our novel immunoprecipitation-immunoassay (IP-IA)...